V600E is the most commonly encountered BRAF mutation. Braftovi – which Pfizer acquired through its $11.4 billion takeover of Array Biopharma in 2019 – was previously approved in combination ...

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...

There’s been an exciting new development for some patients with metastatic colorectal cancer: a groundbreaking FDA approval has introduced a new treatment option specifically designed for those ...

The cost-effectiveness agency has backed the combination of Braftovi (encorafenib) and Eli Lilly's Erbitux (cetuximab) as a second-line treatment option for BRAF V600E mutated mCRC after an ...

Biomarkers, precision medicine, early detection to revolutionize CRC care in India: Dr. Sumant Gupta: Shardul Nautiyal, Mumbai Saturday, April 12, 2025, 08:00 Hrs [IST] Molecular ...

standard of care in untreated BRAF V600E-mutant metastatic colorectal cancer. Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in ...

Less than one-quarter of oncologists surveyed indicated that every one of their patients with advanced gastric or gastroesophageal junction cancers received biomarker testing consistent with practice ...

In combination with trametinib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. Not for treatment of colorectal cancer ...